List of works - Simon J Cook

A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr(286), not Thr(288).

scientific article published on January 2014

Adaptation to chronic mTOR inhibition in cancer and in aging.

scientific article published on August 2013

Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation.

scientific article published on 20 December 2013

CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIMEL.

scientific article published on 8 September 2011

Calcium phosphate particles stimulate interleukin-1β release from human vascular smooth muscle cells: A role for spleen tyrosine kinase and exosome release.

scientific article published on 20 December 2017

Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signalling.

scientific article

DYRK1A-mediated Cyclin D1 Degradation in Neural Stem Cells Contributes to the Neurogenic Cortical Defects in Down Syndrome

scientific article

De-RSKing ERK - regulation of ERK1/2-RSK dissociation by phosphorylation within a disordered motif

scientific article published in January 2018

Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2

scientific article published on 20 November 2019

ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway

scientific article published on 15 February 2018

ERK1/2 signalling protects against apoptosis following endoplasmic reticulum stress but cannot provide long-term protection against BAX/BAK-independent cell death.

scientific article published on 20 September 2017

Epigenetic memory of the first cell fate decision prevents complete ES cell reprogramming into trophoblast.

scientific article published on 26 November 2014

FGF signaling inhibition in ESCs drives rapid genome-wide demethylation to the epigenetic ground state of pluripotency

scientific article published on 11 July 2013

Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.

scientific article published on 7 September 2015

Inhibitory feedback control of NF-κB signalling in health and disease

publication published on 01 July 2021

Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer

scientific article

MEK inhibitor U0126 reverses protection of axons from Wallerian degeneration independently of MEK-ERK signaling

scientific article published in 2013

MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road

scientific article published on September 2015

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF amplification whereas KRAS amplification promotes EMT-chemoresistance

scientific article published on 02 May 2019

Maternal DNA Methylation Regulates Early Trophoblast Development

scientific article published on January 2016

Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia.

scientific article

Oncogenic K-Ras suppresses IP₃-dependent Ca²⁺ release through remodelling of the isoform composition of IP₃Rs and ER luminal Ca²⁺ levels in colorectal cancer cell lines.

scientific article published on 12 February 2014

Over-expressed, N-terminally truncated BRAF is detected in the nucleus of cells with nuclear phosphorylated MEK and ERK

scientific article published on 20 December 2018

Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors

scientific article published on 13 March 2020

RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence

scientific journal article

Stimulating translational research: several European life science institutions put their heads together

scientific article published on 5 August 2015

Targeting IKKβ in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKKβ Inhibitors

scientific article published on 23 August 2018

Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

scientific article published on 14 November 2019

That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.

scientific article published on August 2013

The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G₁ cell-cycle arrest and not a direct effect on BIK protein stability

scientific article published on May 2014

The role of MAPK signalling pathways in the response to endoplasmic reticulum stress

scientific article published on 15 January 2014

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.

scientific article published on February 2016

Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling ⬇️

scientific article published on February 1, 2012

Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance ⬇️

scientific article published on August 6, 2012

V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a

scientific article published on November 2010

Visualization of Endogenous ERK1/2 in Cells with a Bioorthogonal Covalent Probe.

scientific article

List of works by Simon J Cook

A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr(286), not Thr(288).

Adaptation to chronic mTOR inhibition in cancer and in aging.

Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation.

CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIMEL.

Calcium phosphate particles stimulate interleukin-1β release from human vascular smooth muscle cells: A role for spleen tyrosine kinase and exosome release.

Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signalling.

DYRK1A-mediated Cyclin D1 Degradation in Neural Stem Cells Contributes to the Neurogenic Cortical Defects in Down Syndrome

De-RSKing ERK - regulation of ERK1/2-RSK dissociation by phosphorylation within a disordered motif

Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2

ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway

ERK1/2 signalling protects against apoptosis following endoplasmic reticulum stress but cannot provide long-term protection against BAX/BAK-independent cell death.

Epigenetic memory of the first cell fate decision prevents complete ES cell reprogramming into trophoblast.

FGF signaling inhibition in ESCs drives rapid genome-wide demethylation to the epigenetic ground state of pluripotency

Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.

Inhibitory feedback control of NF-κB signalling in health and disease

Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer

MEK inhibitor U0126 reverses protection of axons from Wallerian degeneration independently of MEK-ERK signaling

MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF amplification whereas KRAS amplification promotes EMT-chemoresistance

Maternal DNA Methylation Regulates Early Trophoblast Development

Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia.

Oncogenic K-Ras suppresses IP₃-dependent Ca²⁺ release through remodelling of the isoform composition of IP₃Rs and ER luminal Ca²⁺ levels in colorectal cancer cell lines.

Over-expressed, N-terminally truncated BRAF is detected in the nucleus of cells with nuclear phosphorylated MEK and ERK

Paradoxical activation of the protein kinase-transcription factor ERK5 by ERK5 kinase inhibitors

RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence

Stimulating translational research: several European life science institutions put their heads together

Targeting IKKβ in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKKβ Inhibitors

Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.

The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G₁ cell-cycle arrest and not a direct effect on BIK protein stability

The role of MAPK signalling pathways in the response to endoplasmic reticulum stress

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.

Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling ⬇️

Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance ⬇️

V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a

Visualization of Endogenous ERK1/2 in Cells with a Bioorthogonal Covalent Probe.